Traws Pharma, INC DEF 14A proxy statements

Traws Pharma, Inc. has issued its 2026 proxy statement detailing director elections, equity plan amendments, and capital raise approvals.

TRAWS PHARMA, INC. announces details for its 2025 Annual Meeting, including proposals for director elections, compensation plan amendments, and auditor ratification.

Traws Pharma, Inc. announces its 2025 Annual Meeting of Stockholders to address director elections, an amended incentive plan, executive compensation, and auditor ratification.

Traws Pharma is holding a special meeting of stockholders to approve the issuance of common stock upon the exercise of warrants issued in a recent private placement, aiming to comply with Nasdaq listing requirements.

Traws Pharma is holding its 2024 Annual Meeting of Stockholders virtually on October 31, 2024, to vote on key proposals including director elections, an incentive compensation plan amendment, executive compensation, and auditor ratification.

Traws Pharma is holding a special meeting to seek stockholder approval for proposals including the issuance of shares upon conversion of preferred stock, an increase in authorized common stock, and a reverse stock split.

Traws Pharma highlights its potential best-in-class product candidates in development for cancer and respiratory viral diseases in a recent investor presentation.

Onconova Therapeutics and Trawsfynydd Therapeutics have merged to create Traws Pharma, a company focused on developing antiviral and oncology treatments, backed by a $14 million private placement.